Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, Non-Hodgkin 16Myelodysplastic Syndromes 15Leukemia, Myeloid, Acute 15Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Lymphoma, Mantle-Cell 14Multiple Myeloma 13Waldenstrom Macroglobulinemia 12Graft vs Host Disease 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Leukemia 11Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Sarcoma 9Myeloproliferative Disorders 9Burkitt Lymphoma 9Tuberous Sclerosis 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Primary Myelofibrosis 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Congenital Abnormalities 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, Large-Cell, Anaplastic 5Lymphangioleiomyomatosis 5

Interventions

Everolimus 3Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Autistic Disorder × Sirolimus × Clear all
NCT01929642 2021-03-29

RAPT

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
3 enrolled 10 charts

Autistic Disorder, Tuberous Sclerosis, Self-Injurious Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡